RevitaCAM

RSS

meloxicam

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for RevitaCAM has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 30/05/2016

Authorisation details

Product details
Name
RevitaCAM
Agency product number
EMEA/V/C/002379
Active substance
meloxicam
International non-proprietary name (INN) or common name
meloxicam
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM01AC06
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
23/02/2012
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

05/10/2015 RevitaCAM - EMEA/V/C/002379 - T/0006

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Anti inflammatory and antirheumatic products
  • non steroids (oxicams)

Therapeutic indication

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in dogs.

Assessment history

How useful was this page?

Add your rating